undamentalytics Newsletter
Sign in

Ligand Pharmaceuticals Inc income statement

In fiscal 2025, Ligand Pharmaceuticals Inc reported revenue of $268m, up 60.4% on the year before, operating income of $41.0m (a 15.3% margin) and net income of $124m, or $6.13 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue39243031496572109141251120164242196131167268254
Cost of revenue———————656————————
Gross profit———————103136245————————
Research and development40221011910112127285641323625218123
General and administrative1513151618232528293842604770537992148
Operating income−10−29−10152027446816480738104312−234126
Interest expense003325—13134836272021358
Net interest income—0−2−3−2−5−12−12−11—————————
Income before tax−10−15−4−4911358571737971723664315953
Income tax−2−3−13−100−192104530167−5−441107351
Net income−2−1010−11112230−213143629−357−3352−412451
Diluted EPS−$0.10−$0.53$0.49−$0.03$0.55$0.56$10.83−$0.08$0.53$5.96$31.85−$0.18$3.31−$1.98$2.94−$0.22$6.13$2.48
Diluted shares (average)19m20m20m20m21m21m21m21m23m24m20m17m17m17m18m18m20m21m
EBITDA−5−27231822305579177825631555548137560

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: LGND vs RYTMANAB vs LGNDLGND vs PHAT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ligand Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ligand Pharmaceuticals Inc.